 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||| 608 / 3SBio
Enrollment open: A Study to Evaluate 608 in Patients with Non- Radiographic Axial Spondyloarthritis (nr-axSpA) (clinicaltrials.gov) - Mar 11, 2025
P2, N=180, Recruiting, Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Not yet recruiting --> Recruiting
- ||| 608 / 3SBio
Enrollment closed: A Study to Evaluate 608 in Patients with Ankylosing Spondylitis (AS) (clinicaltrials.gov) - Oct 23, 2024
P2, N=250, Active, not recruiting, Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Not yet recruiting --> Recruiting Not yet recruiting --> Active, not recruiting
- |||||||||| 608 / 3SBio
New P3 trial: An Phase III Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With PsO (clinicaltrials.gov) - Mar 12, 2024
P3, N=750, Not yet recruiting, Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
- ||||| 608 / 3SBio
New P2 trial: A Study to Evaluate 608 in Patients with Ankylosing Spondylitis (AS) (clinicaltrials.gov) - Feb 15, 2024
P2, N=250, Not yet recruiting, Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
- |||| 608 / 3SBio
New P2 trial: A Study to Evaluate 608 in Patients with Non- Radiographic Axial Spondyloarthritis (nr-axSpA) (clinicaltrials.gov) - Jan 24, 2024
P2, N=180, Not yet recruiting, Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
- |||||| 608 / 3SBio
Enrollment open, Trial primary completion date: A Phase 3 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With Moderate-to-Severe Plaque Psoriasis (clinicaltrials.gov) - Jan 13, 2023
P3, N=450, Recruiting, Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Not yet recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Trial primary completion date: Jun 2024 --> Jul 2023
- || 608 / 3SBio
Enrollment closed: A Phase 2 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With Moderate-to-Severe Plaque Psoriasis (clinicaltrials.gov) - Nov 8, 2022
P2, N=139, Active, not recruiting, Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Not yet recruiting --> Recruiting | Trial primary completion date: Jun 2024 --> Jul 2023 Recruiting --> Active, not recruiting
- |||| 608 / 3SBio
New P2 trial: A Phase 2 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With Moderate-to-Severe Plaque Psoriasis (clinicaltrials.gov) - Nov 3, 2022
P2, N=139, Recruiting, Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
- |||| 608 / 3SBio
Trial primary completion date: A Phase 3 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With Moderate-to-Severe Plaque Psoriasis (clinicaltrials.gov) - Oct 19, 2022
P3, N=450, Not yet recruiting, Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Recruiting --> Active, not recruiting Trial primary completion date: Sep 2023 --> Jun 2024
- |||||||||| 608 / 3SBio
New P3 trial: A Phase 3 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With Moderate-to-Severe Plaque Psoriasis (clinicaltrials.gov) - Sep 13, 2022
P3, N=450, Not yet recruiting, Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
- ||| 608 / 3SBio
New P1 trial: Randomized, Double Blinded, Placebo Controlled, Single Dose Escalation Study of 608 in Healthy Subjects (clinicaltrials.gov) - Apr 28, 2020
P1, N=62, Recruiting, Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.